Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,077

Employees1,077

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,077

Employees1,077

EXEL Key Statistics

Market cap

12.56B

Market cap12.56B

Price-Earnings ratio

16.39

Price-Earnings ratio16.39

Dividend yield

—

Dividend yield—

Average volume

3.33M

Average volume3.33M

High today

$50.48

High today$50.48

Low today

$48.66

Low today$48.66

Open price

$49.82

Open price$49.82

Volume

991.56K

Volume991.56K

52 Week high

$50.48

52 Week high$50.48

52 Week low

$33.76

52 Week low$33.76

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $49.96. The company's market cap stands at 12.56B, with a P/E ratio of 16.39.

On 2026-05-13, Exelixis(EXEL) stock traded between a low of $48.66 and a high of $50.48. Shares are currently priced at $49.96, which is +2.7% above the low and -1.0% below the high.

The Exelixis(EXEL)'s current trading volume is 991.56K, compared to an average daily volume of 3.33M.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $50.48 and a 52-week low of $33.76.

EXEL News

Simply Wall St 2d

Three High ROE Stocks With Quietly Powerful Balance Sheets

Markets are wrestling with higher inflation, rising bond yields and volatile energy prices, so quality balance sheets matter more than ever. When borrowing cost...

Simply Wall St 4d

A Look At Exelixis Valuation After Strong Q1 2026 Results And Zanzalintinib FDA Milestone

Advertisement Why Exelixis stock is on investors’ radar after Q1 2026 Exelixis (EXEL) is back in focus after first quarter 2026 earnings, with revenue of US$6...

TipRanks 6d

Exelixis price target raised to $50 from $49 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $50 from $49 and keeps an Equal Weight rating on the shares after the company shared updates...

Analyst ratings

48%

of 21 ratings

Buy

47.6%

Hold

47.6%

Sell

4.8%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.